Clinical Trial Update: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy [Phase 2]

View source ↗

Summary

Phase 2 trial update on subretinal administration of CNTO 2476 in geographic atrophy, reporting safety and clinical response outcomes with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• CNTO 2476

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Visual Acuity, Geographic Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2020-06-23